α-Globin as a molecular target in the treatment of β-thalassemia
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The thalassemias, together with sickle cell anemia and its variants, are the world’s most common form of inherited anemia, and in economically undeveloped countries, they still account for tens of thousands of premature deaths every year. In developed countries, treatment of thalassemia is also still far from ideal, requiring lifelong transfusion or allogeneic bone marrow transplantation. Clinical and molecular genetic studies over the course of the last 50 years have demonstrated how coinheritance of modifier genes, which alter the balance of α-like and β-like globin gene expression, may transform severe, transfusion-dependent thalassemia into relatively mild forms of anemia. Most attention has been paid to pathways that increase γ-globin expression, and hence the production of fetal hemoglobin. Here we review the evidence that reduction of α-globin expression may provide an equally plausible approach to ameliorating clinically severe forms of β-thalassemia, and in particular, the very common subgroup of patients with hemoglobin E β-thalassemia that makes up approximately half of all patients born each year with severe β-thalassemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Genome editing with engineered zinc finger nucleases
Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S., & Gregory, P. D. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2842 · Cited by 2,285
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV
Tebas, P., Stein, D., Tang, W. W., Frank, I., Wang, S. Q., Lee, G., Spratt, S. K., Surosky, R. T., Giedlin, M. A., Nichol, G., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300662 · Cited by 1,357
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
Harteveld, C. L., & Higgs, D. R. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-13 · Cited by 508
Self-citationAbnormal RNA processing due to the exon mutation of βE-globin gene
Orkin, S. H., Kazazian, H. H., Antonarakis, S. E., Ostrer, H., Goff, S. C., & Sexton, J. P. (1982) · Nature · doi:10.1038/300768a0 · Cited by 298
Reawakening fetal hemoglobin: prospects for new therapies for the β-globin disorders
Bauer, D. E., Kamran, S. C., & Orkin, S. H. (2012) · Blood · doi:10.1182/blood-2012-06-292078 · Cited by 177
HSP70 sequestration by free α-globin promotes ineffective erythropoiesis in β-thalassaemia
Arlet, J.-B., Ribeil, J.-A., Guillem, F., Negre, O., Hazoume, A., Marcion, G., Beuzard, Y., Dussiot, M., Moura, I. C., Demarest, S., et al. (2014) · Nature · doi:10.1038/nature13614 · Cited by 151
Cited by
Molecular basis of α-thalassemia
Farashi, S., & Harteveld, C. L. (2018) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2017.09.004 · Cited by 227
Molecular Basis and Genetic Modifiers of Thalassemia
Mettananda, S., & Higgs, D. R. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.11.003 · Cited by 130
Self-citationOral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia
Manolova, V., Nyffenegger, N., Flace, A., Altermatt, P., Varol, A., Doucerain, C., Sundstrom, H., & Dürrenberger, F. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129382 · Cited by 98
“Precipitated α-globin aggregates contain heme and iron, which generate ROS leading to a shortened life span of RBCs, anemia, and tissue hypoxia (3, 4).”
BackgroundCustomizing the genome as therapy for the β-hemoglobinopathies.
Canver, M. C., & Orkin, S. H. (2016) · Blood · doi:10.1182/blood-2016-01-678128 · Cited by 61
Metadata
- Authors
- Mettananda, S., Gibbons, R. J., & Higgs, D. R.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2015-06-11
- Volume
- 125
- Issue
- 24
- Pages
- 3694-3701
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1785988192
- Cited by
- 132
- References
- 11
- FWCI
- 5.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: α-Globin as a molecular target in the treatment of β-thalassemia. https://app.cochat.ai/papers/10.1182/blood-2015-03-633594
- The paper
- Mettananda, S., Gibbons, R. J., & Higgs, D. R. (2015). α-Globin as a molecular target in the treatment of β-thalassemia. Blood. https://doi.org/10.1182/blood-2015-03-633594
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.